Peptides from antibodies to DNA elicit cytokine release from peripheral blood mononuclear cells of patients with systemic lupus erythematosus: Relation of cytokine pattern to disease duration

Lupus

Volumn 13, Issue 7, 2004, Pages 490-500

  Kalsi, J K ^a   Grossman, J ^a   Kim, J ^a   Sieling, P ^a   Gjertson, D W ^b   Reed, E F ^b   Ebling, F M ^a   Linker Israeli, M ^c   Hahn, B H ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA Immunogenetics Center   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoantibodies; Cytokines; DR DQ haplotypes; Lupus; Peptides

Indexed keywords

ANTIGEN; AUTOANTIBODY; CYTOKINE; DNA ANTIBODY; GAMMA INTERFERON; HLA D ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; PEPTIDE;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE DURATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENOTYPE; HAPLOTYPE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MOLECULAR TYPING; MONONUCLEAR CELL; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

AMINO ACID SEQUENCE; AUTOANTIBODIES; CYTOKINES; DNA; ENZYME-LINKED IMMUNOSORBENT ASSAY; HISTOCOMPATIBILITY TESTING; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; REFERENCE VALUES; TIME FACTORS;

EID: 4043149909     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203303lu1060oa     Document Type: Article

References (45)

1. Hahn BH. Mechanisms of disease: antibodies to DNA. N Engl J Med 1998; 338: 1359-1368.
2. Dieker JW, van der Vlag J, Berden JH. Triggers for anti-chromatin autoantibody production in SLE. Lupus 2002; 11: 856-864.
3. Kaliyaperumal A, Michaels MA, Datta SK. Naturally processed chromatin peptides reveal a major autoepitope that primes pathogenic T and B cells of lupus. J Immunol 2002; 168: 2530-2537.
4. Pisetsky DS. The role of bacterial DNA in autoantibody induction. Curr Top Microbiol Immunol 2000; 247: 143-155.
5. Williams WW, Staines NA, Muller S, Isenberg DA. Human T cell responses to autoantibody variable region peptides. Lupus 1995; 4: 464-471.
6. Kalsi JK, Hahn BH. The role of VH determinants in systemic lupus erythematosus. Lupus 2002; 11: 878-884.
7. Dayan M, Segal R, Sthoeger Z et al. Immune response of SLE patients to peptides based on the complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. J Clin Immunol 2000; 20: 187-194.
8. 1 mouse model of systemic lupus erythematosus. Arthritis Rheum 1993; 36: 355-363.
9. Brosh N, Dayan M, Fridkin M, Mozes E. A peptide based on the CDR3 of an anti-DNA antibody of experimental SLE origin is also a dominant T-cell epitope in (NZBxNZW)F1 mice. Immunol Lett 2000; 72: 61-68.
10. Singh RR, Hahn BH, Tsao BP, Ebling FM. Evidence for multiple mechanismg of polyclonal T cell activation in murine lupus: determinant spreading, degenerate recognition of T cells, and molecular mimicry initiated by self-Ig peptides. J Clin Invest 1998; 102: 1841-1865.
11. Shoenfeld Y, Mozes E. Pathogenic idiotypes of autoantibodies in autoimmunity: lessons from new experimental models of SLE. FASEB J 1990; 4: 2646-2651.
12. Hahn BH, Singh RR, Wong WK, Bulpitt K, Tsao BP, Ebling FM. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum 2001; 44: 432-441.
13. Eilat E, Dayan M, Zinger H, Mozes E. The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA autoAb ameliorates experimental systemic lupus erythematosus. Proc Natl Acad Sci USA 2001; 98: 1148-1153.
14. Linker-Israeli M, Ebling FM, Wallace DJ et al. T cells of SLE patients recognize VH determinants of anti-dsDNA autoantibodies. Arthritis Rheum 1996; 39: S267 (abstract).
15. Singh RR, Ebling FM, Sercarz EE, Hahn BH. Immune tolerance to autoantibody-derived peptides delays development of autoimmunity in murine lupus. J Clin Invest 1995; 96: 2990-2996.
16. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
17. Hochberg MG. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus (letter). Arthritis Rheum 1997; 40: 1725.
18. Petri M, Buyon J, Skovron ML et al. Reliability of SELENA SLEDAI and flares as a clinical trial outcome measure. Arthritis Rheum 1998; 41: S218 (abstract).
19. Ward MM, Marx AS, Barry NN. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol 2000; 27: 634-643.
20. Tsao BP, Ebling F, Roman C, Panosian-Sahakian N, Calame K, Hahn BH. Structural characteristics of the variable regions of an immunoglobulin gene coding a pathogenic autoantibody in murine lupus. J Clin Invest 1990; 85: 530-540.
21. Blanco F, Longhurst C, Watts R et al. Identification and characterization of a new human DNA reactive monoclonal Ab and a common idiotype WRI 176 Id beta. Lupus 1994; 3: 15-24.
22. Paul E, Diamond B. Characterization of two human anti-DNA Abs bearing the pathogenic idiotype 8.12. Autoimmunity 1993; 16: 13-21.
23. Cairns E, Kwong PC, Misener V, Ip P, Bell DA, Siminovitch KA. Analysis of variable region genes encoding a human anti-DNA antibody of normal origin. Implications for the molecular basis of human autoimmune responses. J Immunol 1989; 143: 685-691.
24. Demaison C, Chastagner P, Theze J, Zouali M. Somatic diversification in the heavy chain variable region genes expressed by human autoantibodies bearing a lupus-associated nephritogenic anti-DNA idiotype. Proc Natl Acad Sci USA 1994; 91: 514-518.
25. Lu L, Kaliyaperumal A, Boumpas DT, Datta SK. Major peptide autoepitopes for nucleosome-specific T cells of human lupus. J Clin Invest 1999; 104: 345-355.
26. Voll RE, Roth EA, Girkontaite I et al. Histone-specific Th0 and Th1 clones derived from systemic lupus erythematosus patients induce double-stranded DNA antibody production. Arthritis Rheum 1997; 40: 2162-2171.
27. Helms T, Boehm BO, Asaad RJ, Trezza RP, Lehmann PV, Tary-Lehmann M. Direct visualization of cytokine-producing recall antigen-specific CD4 memory T cells in healthy individuals and HIV patients. J Immunol 2000; 164: 3723-3732.
28. Graham RR, Ortmann WA, Langefeld CD et al. Visualizing human leukocyte antigen class II risk haplotypes in human systemic lupus erytyematosus. Am J Hum Genet 2002; 71: 543-553.
29. Weiss A, Samelson LE. T-Lymphocyte activation. In Paul WE ed. Fundamental immunology. Philadelphia: Lippincott Williams & Wilkins, 2003; 321.
30. Singh RR, Hahn BH. T-B cell determinant spreading develops spontaneously in murine lupus: implications for pathogenesis. Immunol Rev 1998; 164: 201-208.
31. Tian J, Gergori S, Adorini L, Kaufman DL. The frequency of high avidity T cells determine the hierarchy of determinant spreading. J Immunol 2001; 166: 7144-7150.
32. Mason LJ, Timothy LM, Isenberg DA, Kalsi JK. Immunization with a peptide of Sm B/B' results in limited epitope spreading but not autoimmune disease. J Immunol 1999; 162: 5099-5105.
33. Deshmukh US, Gaskin F, Lewis JE, Kannapell CC, Fu SM. Mechanisms of autoantibody diversification to SLE-related autoantigens. Ann NY Acad Sci 2003; 987: 91-98.
34. Ronnelid J, Tejde A, Mathsson L, Nilsson-Ekdahl K, Nilsson B. Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanisms: implications for a possible vicious cycles maintaining B cell hyperactivity in SLE. Ann Rheum Dis 2003; 62: 37-42.
35. Tyrrell-Price J, Lydyard PM, Isenberg DA. The effect of interleukin-10 and interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus. Clin Exp Immunol 2001; 124: 118-125.
36. Csiszar A, Nagy G, Gergely P, Pozsonyi T, Pocsik E. Increased interferon-gamma, IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol 2000; 122: 464-470.
37. Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Klareskog L, Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 2000; 18: 565-570.
38. Llorente L, Richaud-Patin Y, Garcia-Padilla C et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000; 43: 1790-1800.
39. Del Prete G. The concept of type-1 and type-2 helper T cells and their cytokines in humans. Int Rev Immunol 1998; 16: 427-455.
40. Singh FK, Mehrotra S, Agarwal SS. The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol Res 1999; 20: 147-161.
41. Horwitz DA, Gray JD, Behrendsen SC et al. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Arthritis Rheum 1998; 441: 838-844.
42. Akahoshi M, Nakashima H, Tanaka Y et al. Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 1644-1648.
43. Uhm WS, Na K, Song GW et al. Cytokine balance in kidney tissue from lupus nephritis patients. Rheumatology (Oxford) 2003; 42: 935-938.
44. Gardner EM, Muraski DM. Age-related changes in type 1 and type 2 cytokine production in humans. Biogerontology 2002; 3: 271-290.
45. Zandman-Goddard G, Shoenfeld Y. Novel approaches to therapy for systemic lupus erythematosus. Eur J Intern Med 2000; 11: 130-134.